Trial Profile
An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Talactoferrin alfa (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 05 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.